Non-Small Cell Lung Cancer Market Summary
According to DelveInsight’s analysis, the Non-Small Cell Lung Cancer market size was found to be approximately USD 33 billion in the leading markets – the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan – in 2025. With growing incident cases, accelerating pipeline activity, and a rapidly evolving treatment landscape, the NSCLC market is positioned for substantial expansion through the forecast period of 2026–2036.
The surge in targeted therapies, antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and next-generation tyrosine kinase inhibitors (TKIs) continues to reshape how NSCLC is diagnosed and managed globally, offering new hope to hundreds of thousands of patients diagnosed each year.
NSCLC Overview and Diagnosis
Lung cancer primarily originates in the lungs and may spread to lymph nodes or distant organs such as the brain through a process called metastasis. It is broadly classified into two types – small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancers, making it by far the more prevalent of the two subtypes. Compared with NSCLC, SCLC is more aggressive, spreads rapidly, and can become fatal within weeks if left untreated.
NSCLC is further classified into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, with less common types including adenosquamous and sarcomatoid carcinomas. NSCLC arises from epithelial cells along the respiratory tract, from central bronchi to terminal alveoli, and is generally less sensitive to chemotherapy and radiation therapy than SCLC. Though strongly associated with cigarette smoking, adenocarcinoma also occurs in never-smokers. Histological subtype often correlates with site of origin – squamous cell carcinoma typically develops near central bronchi, while adenocarcinoma and bronchioloalveolar carcinoma usually arise in peripheral lung tissue. Common symptoms shared by both NSCLC and SCLC include persistent cough, chest pain, shortness of breath, wheezing, loss of appetite, unexplained weight loss, and chronic fatigue.
Non-Small Cell Lung Cancer (NSCLC) Unmet Needs
Despite notable therapeutic advances, significant gaps persist in NSCLC care. The Non-Small Cell Lung Cancer market research by DelveInsight identifies critical unmet needs shaping the future of treatment development. Antibiotic-associated ICI resistance in NSCLC continues to limit immunotherapy efficacy in a meaningful subset of patients, while the high cost of combination therapies creates access barriers across geographies. Reimbursement challenges in Europe remain a persistent obstacle, particularly for newer biologics and ADCs. Treatment gaps in molecularly driven NSCLC – including limited post-TKI options and challenges with exon 20 mutations – continue to affect outcomes, alongside late-stage diagnosis in the majority of patients and restricted immunotherapy data in specific molecular subgroups. Addressing these gaps represents one of the most urgent priorities for researchers, policymakers, and the biopharmaceutical industry alike.
Gain actionable insights into NSCLC pipeline therapies, market sizing, and clinical trial updates to strengthen your strategic decision-making in the NSCLC indication.
Non-Small Cell Lung Cancer (NSCLC) Epidemiology
Based on DelveInsight’s assessment, the 7 Major Markets (7MM) had approximately 539,000 incident cases of NSCLC in 2025. These figures are expected to rise owing to the growing at-risk population and advancements in diagnostic capabilities throughout the forecast period (2026–2036). Key epidemiological highlights include:
- The US accounted for the highest incident NSCLC cases among the 7MM in 2025, followed by Japan, with Spain reporting the fewest cases
- Germany recorded the highest number (~57,000) of NSCLC cases among the EU4 and the UK, while Spain had the lowest (~27,000)
- NSCLC is slightly more common in men than women; however, incidence in persons under 65 years is rising alarmingly
- Most cases continue to be diagnosed at advanced Stage IV due to delayed detection, limited screening access, nonspecific early symptoms, and socioeconomic barriers to timely healthcare
- Diagnoses at early Stage I have increased, largely driven by wider use of low-dose CT screening in high-risk individuals and incidental findings during imaging performed for other medical conditions
- Incidence of Stage II–III disease has remained relatively stable across the forecast markets
- The rising incidence of adenocarcinoma is partly attributed to improved evaluation and reporting practices, sustained smoking trends, and a slower post-cessation risk decline compared with squamous cell carcinoma
NSCLC Therapies
The current NSCLC therapy landscape spans multiple modalities including targeted TKIs, immune checkpoint inhibitors, ADCs, and investigational bispecific antibodies. Key therapies in this space include Osimertinib (TAGRISSO), Afatinib maleate (GILOTRIF/GIOTRIF), Dacomitinib (VIZIMPRO), Mobocertinib (EXKIVITY), Aumolertinib mesylate (AUMSEQA), Sunvozertinib (ZEGFROVY), Amivantamab (RYBREVANT), Datopotamab deruxtecan (DATROWAY), Necitumumab (PORTRAZZA), Pembrolizumab (KEYTRUDA), Nivolumab (OPDIVO), Atezolizumab (TECENTRIQ), BMS-986504, Izalontamab brengitecan (Iza-bren), Neladalkib (NVL-655), PF-08046054 (SGN-PDL1V), Telisotuzumab adizutecan (Temab-A, ABBV-400), Daraxonrasib (RMC-6236), Niraparib (ZEJULA), Rilvegostomig (AZD2936), Pumitamig (BNT327/PM8002), Aglatimagene besadenovec (CAN-2409), Gotistobart (BNT316, ONC-392), Retifanlimab-dlwr (ZYNYZ), and others.
Leading Non-Small Cell Lung Cancer Companies
The leading Non-Small Cell Lung Cancer Companies actively developing therapies in this space include:
- AstraZeneca
- Boehringer Ingelheim
- Pfizer
- Takeda
- Johnson & Johnson Innovative Medicine
- Eli Lilly and Company
- Merck
- Bristol-Myers Squibb
- Roche
- Shanghai Henlius Biotech
- AbbVie
- Daiichi Sankyo
- Nuvation Bio
- PDC*line Pharma
- Moderna Therapeutics
- Pfizer
- GSK
- Gilead Sciences
- BieGene
- Nuvalent
- Othersand others.
Approved Therapies for NSCLC
Recent regulatory milestones reflect the accelerating pace of NSCLC drug approvals across geographies:
- AUMSEQA (Aumolertinib) – Jiangsu Hansoh Pharmaceutical: Aumolertinib is a third-generation EGFR-TKI for the treatment of locally advanced or metastatic NSCLC with activating EGFR mutations, including EGFR T790M-positive disease. In June 2025, the UK MHRA granted marketing authorization to aumolertinib mesilate tablets as monotherapy for these indications.
- TEVIMBRA (Tislelizumab) – BeiGene: TEVIMBRA is a humanized IgG4 anti-PD-1 monoclonal antibody with high affinity and specificity for PD-1, designed to minimize Fcγ receptor binding and enhance immune-mediated tumor recognition. In August 2025, the European Commission approved it in combination with platinum-based chemotherapy as neoadjuvant therapy, followed by TEVIMBRA monotherapy as adjuvant treatment for adults with resectable NSCLC at high risk of recurrence.
- HERNEXEOS (Zongertinib) – Boehringer Ingelheim: Zongertinib is an investigational oral HER2-specific TKI being developed for HER2 (ERBB2)-mutant NSCLC. In September 2025, Boehringer Ingelheim received approval in Japan for HERNEXEOS – the first oral targeted therapy for previously treated HER2-mutant advanced NSCLC. In November 2025, the FDA granted zongertinib a Commissioner’s National Priority Voucher (CNPV), recognizing its potential to address this rare and aggressive cancer.
Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis
The NSCLC pipeline continues to advance across multiple modalities, with several pivotal readouts expected in the near term:
- Iza-bren (Izalontamab brengitecan) – SystImmune and Bristol Myers Squibb: Izalontamab brengitecan is a first-in-class bispecific EGFR×HER3 ADC that simultaneously blocks EGFR/HER3 signaling and delivers a cytotoxic payload to induce cancer cell death. It shows potential as monotherapy or in combination with osimertinib for EGFR-mutant NSCLC. Phase II results in metastatic or unresectable NSCLC and other solid tumors were presented at ESMO 2025.
- Daraxonrasib (RMC-6236) – Revolution Medicines: Daraxonrasib is an oral, multi-selective RAS(ON) inhibitor designed to block active RAS signaling and target multiple oncogenic RAS mutations (G12X, G13X, Q61X) across cancers including NSCLC, PDAC, and CRC. In November 2025, Revolution Medicines announced plans to initiate a registrational trial in 2026 evaluating daraxonrasib with pembrolizumab and chemotherapy as first-line treatment for metastatic RAS-mutant NSCLC.
Non-Small Cell Lung Cancer (NSCLC) Drug Updates
The pipeline continues to generate significant near-term milestones. Nuvalent anticipates the submission of an NDA for neladalkib in TKI-pretreated ALK-positive NSCLC in the first half of 2026. Revolution Medicines plans to initiate a registrational trial in 2026 evaluating daraxonrasib combined with pembrolizumab and chemotherapy as first-line treatment in metastatic RAS-mutant NSCLC. The IOV-LUN-202 trial is expected to complete enrollment in 2026, supporting a supplemental BLA for lifileucel in nonsquamous NSCLC with a potential commercial launch in the second half of 2027. MK-1084’s KANDLELIT-004 study anticipates a data readout in Q1 2029, marking another important milestone for the evolving NSCLC therapeutic arsenal.
Non-Small Cell Lung Cancer (NSCLC) Market Outlook
With more than 500,000 cases across the 7MM, lung cancer remains one of the leading causes of death worldwide, and the Non-Small Cell Lung Cancer market forecast reflects continued robust momentum across all major biomarker-driven segments. Key market highlights include:
- The total EGFR-mutated NSCLC market in the US was nearly USD 3.8 billion in 2025, with TAGRISSO as the dominant EGFR inhibitor and the first and only targeted therapy to demonstrate survival benefits across all stages of EGFR-mutated NSCLC, approved in more than 100 countries. Landmark trials – AURA, FLAURA, ADAURA, LAURA, and FLAURA2 – have consistently demonstrated significant improvements in progression-free survival and overall survival.
- KEYTRUDA captured the highest anti-PD-1/L1 revenue in NSCLC in 2025 and is broadly regarded as the gold standard of first-line care when combined with platinum chemotherapy, regardless of PD-L1 status.
- The ALK-mutated NSCLC market in the US was approximately USD 1.28 billion in 2025. ALECENSA has become the first approved ALK inhibitor in the adjuvant post-surgical setting, while LORBRENA/LORVIQUA, ZYKADIA, and ALUNBRIG dominate metastatic first-line care due to superior progression-free survival and robust intracranial activity.
- TROP-2-directed ADCs including Dato-DXd, Sacituzumab Tirumotecan, and TRODELVY are being evaluated across multiple lines of therapy. AstraZeneca and Daiichi Sankyo are currently running seven Phase III trials for Dato-DXd across NSCLC indications, following the decision to pivot toward accelerated approval in EGFR-mutated NSCLC.
- LUMAKRAS faces increasing commercial pressure – Q3 2025 sales declined by 2%, continuing a multi-quarter trend – while KRAZATI continues to gain ground in KRAS-mutant NSCLC.
- EXKIVITY was withdrawn in the US, UK, and EU due to insufficient confirmatory data, leaving amivantamab as the primary approved therapy for EGFR exon 20 insertions.
- For c-Met overexpressed NSCLC, no approved therapies currently exist across the 7MM, with companies including AbbVie, Mythic Therapeutics, and Regeneron Pharmaceuticals actively targeting this underserved population.
- Innovation continues in gene therapy approaches such as Reqorsa in combination with osimertinib, alongside next-generation TKIs including sutetinib, silevertinib (BDTX-1535), and JIN-A02, all targeting resistance pathways.
Non-Small Cell Lung Cancer (NSCLC) Drug Uptake
Among the emerging first-line therapies expected to enter the market during the forecast period of 2026–2036 are Zipalertinib (TAS6417) combined with chemotherapy, Furmonertinib/Firmonertinib, Pamvatamig (MCLA-129) with or without osimertinib, Aumolertinib (AUMSEQA), Sunvozertinib (ZEGFROVY), Datopotamab deruxtecan with or without osimertinib (TAGRISSO), Telisotuzumab adizutecan in combination with TAGRISSO, Sutetinib, and JMT101 combined with osimertinib. Firmonertinib, sunvozertinib, and JMT101 in combination with osimertinib are anticipated to be among the first to enter the market by 2027 and are expected to compete closely with established therapies such as RYBREVANT and TAGRISSO across key geographies.
Access the full Non-Small Cell Lung Cancer market report to explore in-depth epidemiology, drug uptake forecasts, and competitive landscape analysis across all 7 Major Markets in the NSCLC indication.
Conclusion
The NSCLC treatment landscape is undergoing rapid and sustained transformation, driven by precision oncology, novel ADCs, next-generation TKIs, and expanding immunotherapy combinations. The Non-Small Cell Lung Cancer market is valued at approximately USD 33 billion across 7MM in 2025, with strong growth anticipated through 2036, supported by rising incident cases and a deep, diverse pipeline. Non-Small Cell Lung Cancer market research highlights over 539,000 annual incident cases globally, with rising early-stage diagnoses driven by wider screening adoption. The leading Non-Small Cell Lung Cancer Companies continue to invest in first-line combinations, resistance-mechanism-targeted agents, and novel molecular subgroups, while the Non-Small Cell Lung Cancer market forecast reflects robust pipeline momentum with multiple regulatory submissions, registrational trials, and approvals expected between 2026 and 2030. Unmet needs including resistance, high therapy costs, reimbursement barriers, and late diagnosis continue to fuel the next generation of drug development.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
